NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Boundless Bio, Inc. (BOLD) Stock Analysis

Boundless Bio, Inc. (BOLD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BOLD

$2.87

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BOLD with… →

BOLD Key Statistics

As of Sep 4, 2026
Trading
Open
$2.87
Previous Close
$2.87
Day's Range
2.86–2.89
52-Week Range
0.96–3.16
Volume
20.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.44
Valuation
Market Cap
$65.29M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.85
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$58.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.75M
1-Year Return
+153.98%
Dividend and dates
Avg Volume
1.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BOLD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+139.17%
2025−58.62%
2024 (partial year)−79.65%

As of September 4, 2026.

BOLD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$58.20M—
2024$0.00−$65.36M—
2023$0.00−$49.43M—
2022$0.00−$45.90M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$63.55M−$58.20M—
2024$0.00—−$73.27M−$65.36M—
2023$0.00—−$54.80M−$49.43M—
2022$0.00—−$46.47M−$45.90M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BOLD Valuation vs Biotechnology Median

Median of 656 stocks
MetricBOLDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Boundless Bio, Inc. (BOLD) at $65.29M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 28.

BOLD last closed at $2.87 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.96 to $3.16. The latest close sits 198.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $58.20M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +153.98%. The stored price history starts on March 28, 2024, and the total return since then is −79.86%. The reported beta is 0.44. Daily returns over the trailing 2 years annualize to a volatility of 90.1%.

Growth & Income

The record shows no dividend for BOLD.

2026 is still running; the price is +139.17% year to date. The record holds one complete calendar year, 2025, which returned −58.62%.

Peer Comparison

Boundless Bio, Inc. (BOLD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Boundless Bio, Inc. BOLD $65.29M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Boundless Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Boundless Bio, Inc.

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit website →